
    
      This is a Phase 2b, multinational, multicenter, randomized, double-blind, placebo controlled,
      parallel group study to evaluate the efficacy and safety of three intravenous (IV) treatment
      regimens of sifalimumab (200, 600, or 1,200 mg) in adult subjects with chronic
      moderately-to-severely active SLE with an inadequate response to standard of care (SOC) for
      SLE.
    
  